The global biotech API manufacturing services market, valued at US$ 38.9 Billion in 2022, is projected to grow at a CAGR of 7.1% from 2023 to 2031, surpassing US$ 73 Billion by 2031. biotech API ...

The pharmaceutical contract manufacturing market offers growth opportunities through outsourcing, driven by demand for ...

During the last decade the business landscape for Active Pharmaceutical Ingredient (API) manufacturing has drastically changed. While significant price erosion has taken place, regulatory requirements ...

Efficiency and adaptability are crucial in the ever-evolving manufacturing industry. As manufacturers adopt advanced technologies like IoT, AI, and cloud computing, the need for seamless integration ...

The track by which API manufacturing processes are prepared for commercial use is comparable to overlapping integrative process evaluations at commercial scale. This ensures the process is ...

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

(MENAFN- IMARC Group) An API (Active Pharmaceutical Ingredient) is the biologically active component of a drug that produces the intended therapeutic effect. It is the essential substance in medicines ...

BEIJING--(BUSINESS WIRE)-- Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive Asset Purchase Agreement to acquire the ...